Exicure, Inc. (NASDAQ:XCUR) Sees Significant Decrease in Short Interest

Exicure, Inc. (NASDAQ:XCURGet Free Report) saw a significant decrease in short interest in the month of January. As of January 31st, there was short interest totalling 211,000 shares, a decrease of 74.3% from the January 15th total of 821,100 shares. Approximately 5.1% of the shares of the company are sold short. Based on an average daily volume of 975,600 shares, the days-to-cover ratio is currently 0.2 days.

Hedge Funds Weigh In On Exicure

Large investors have recently modified their holdings of the stock. Citadel Advisors LLC bought a new position in shares of Exicure in the second quarter valued at about $66,000. UBS Group AG raised its position in shares of Exicure by 1,766.7% in the first quarter. UBS Group AG now owns 186,674 shares of the company’s stock valued at $37,000 after purchasing an additional 176,674 shares during the period. Finally, Goldman Sachs Group Inc. increased its position in Exicure by 329.2% during the first quarter. Goldman Sachs Group Inc. now owns 147,703 shares of the company’s stock worth $29,000 after acquiring an additional 113,293 shares during the period. 46.91% of the stock is owned by institutional investors.

Exicure Price Performance

Shares of XCUR opened at $0.60 on Tuesday. The firm has a market capitalization of $5.16 million, a PE ratio of 0.36 and a beta of 1.24. The company’s 50-day moving average is $0.60 and its 200-day moving average is $0.68. Exicure has a fifty-two week low of $0.36 and a fifty-two week high of $1.50.

About Exicure

(Get Free Report)

Exicure, Inc, an early-stage biotechnology company, develops nucleic acid therapies targeting ribonucleic acid against validated targets. The company's preclinical candidate includes SCN9A that is in preclinical studies for the treatment of chronic pain. It also develops immuno-oncology therapeutics based on its proprietary SNA technology.

Recommended Stories

Receive News & Ratings for Exicure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exicure and related companies with MarketBeat.com's FREE daily email newsletter.